These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38787254)

  • 1. Oncolytic Tanapoxvirus Recombinants Expressing Flagellin C or Mouse Interleukin-2 Are Capable of Regressing Human Triple-Negative Breast Cancer Xenografts in Immuno-Competent BALB/c Nude Mice.
    Monaco ML; Filpi GA; Kohler SL; Eversole R; Idris OA; Essani K
    Pathogens; 2024 May; 13(5):. PubMed ID: 38787254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
    Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
    Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
    Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.
    Haller SD; Essani K
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.
    Conrad SJ; El-Aswad M; Kurban E; Jeng D; Tripp BC; Nutting C; Eversole R; Mackenzie C; Essani K
    J Exp Clin Cancer Res; 2015 Feb; 34(1):19. PubMed ID: 25887490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.
    Zhang T; Suryawanshi YR; Kordish DH; Woyczesczyk HM; Jeng D; Essani K
    Virus Genes; 2017 Feb; 53(1):52-62. PubMed ID: 27738905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.
    Zhang T; Kordish DH; Suryawanshi YR; Eversole RR; Kohler S; Mackenzie CD; Essani K
    Curr Cancer Drug Targets; 2018; 18(6):577-591. PubMed ID: 28669340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
    Zhang T; Essani K
    Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
    Gholami S; Marano A; Chen NG; Aguilar RJ; Frentzen A; Chen CH; Lou E; Fujisawa S; Eveno C; Belin L; Zanzonico P; Szalay A; Fong Y
    Breast Cancer Res Treat; 2014 Dec; 148(3):489-99. PubMed ID: 25391896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.
    Gholami S; Chen CH; Gao S; Lou E; Fujisawa S; Carson J; Nnoli JE; Chou TC; Bromberg J; Fong Y
    Cancer Gene Ther; 2014 Jul; 21(7):283-9. PubMed ID: 24924199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
    Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.